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Interferon gamma-mediated renal MHC expression in mercuric chlo-
ride-induced glomerulonephritis. In rodents, mercuric chloride (HgCI2) 
causes an autoimmune disorder with glomerulonephritis (GN), and 
represents an animal model for the pathogenesis of GN. We have tested 
the hypothesis that HgCl2 induces major histocompatibility complex (MHC) expression in renal parenchymal cells, and studied the kinetics 
of this induction and its temporal relation to the development of 
immune complex deposition in the glomeruli. Mice treated with doses 
of HgCl2 between 2 and 3.2 mglkg three times for one week had 
increased renal expression of MHC class I and class II (at the mRNA 
and the product levels). Class I induction was observed in proximal 
tubule cells, endothelial cells and glomerular cells. Class II induction 
was seen mainly in interstitial cells and, to a lesser extent, in tubule 
cells. Rimal MHC expression was maximal at one week, decreased 
progressively after the second week of HgCl2 administration, and 
reached basal levels by 23 weeks. In contrast, the amount of lympho-
cyte infiltration in the kidney increased from the first to the fifth week 
and was followed by the appearance of glomerular immune deposits 
from the third week on. Glomerular immune complex deposits were 
maximal at five weeks and, by 23 weeks, immune deposits in HgCI2-
treated mice were only slightly increased over those observed in the 
sham group. Renal MHC induction by HgCl2 was significantly reduced 
by treatment with monoclonal antibody against interferon y. Our results 
indicate that, in the early phase of HgCl2-induced GN, there is 
induction of expression for MHC class I and II products, mediated by 
interferon-gamma (INF-y), and raise the possibility that the induction of 
MHC expression or other changes in gene expression induced by INF-y 
may be involved in the later development of autoimmune renal injury. 
Major histocompatibility complex (MHC) products are mo-
lecular structures for antigen (Ag) presentation: class II MHC 
products to CD4+ T cells and class I products to CD8+ T cells 
[1]. Increased renal expression of MHC products has been 
observed during various kidney diseases in animals and in 
humans, including glomerulonephritis and rejecting kidney al-
lografts [2-5]. The pathogenetic relevance of increased MHC 
expression is uncertain, but it has been postulated to playa role 
in the pathogenesis of autoimmune reactions by aberrant 
expression of altered self-MHC products. In addition, MHC 
induction is a reflection of cytokines acting on the tissue, 
especially interferon-gamma (INF-'}'), and is a marker for 
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changes in the expression of other INF-y-responsive genes, that 
can be potentially involved in autoimmunity. 
We decided to study the changes in MHC expression, and the 
mechanisms and kinetics of these changes, in an animal model 
of glomerulonephritis (ON). Administration of low, non-neph-
rotoxic doses of mercuric chloride (HgCI2) to rodents induces a 
systemic disease associated with ON [6, 7]. Originally de-
scribed in the rat, the disease is less severe in the mouse, and 
the extrarenal component is milder [8, 9]. The pathogenetic 
mechanism proposed for HgCl2-induced autoimmunity is a T 
cell-dependent polyclonal B cell activation which leads to 
hypergammaglobulinemia (with IgE predominance) and the 
production of autoantibodies against various nuclear and base-
ment membrane components [10]. Autoreactive T cells have 
been described in this model, some of them directed against 
class II MHC products [11, 12]. This disorder is self-limited, 
and the susceptibility to it is genetically determined [6, 7]. 
Recently, Aten et ai, using an immunohistochemical ap-
proach, showed an increased expression of MHC class I and 
class II products in rat tongue and salivary glands, but not in 
epithelial cells of the kidney during HgClz-induced autoimmu-
nity [13]. Rats are unusual in having high basal expression of 
class I and low basal tubular expression of class II MHC 
products [2, 14], making it difficult to evaluate quantitative 
changes in MHC expression. Moreover, MHC-expressing infil-
trating cells may obscure parenchymal cell expression of MHC 
products. 
In this study, we tested the hypothesis that HgCI2 induces an 
increase in MHC mRNA and products in murine kidney. In the 
mouse, basal levels of class I and class II expression in the 
kidney are very low, and HgCl2-induced Iymphoproliferation is 
less intense than in the rat. Our results show that HgCI2 causes 
an early induction of class I and class II MHC expression in 
renal parenchymal cells. This induction ca.n be blocked by 
administration of anti-interferon-'}' (INF-'}') monoclonal anti-
body (mAb), indicating that this cytokine plays an essential role 
in this phenomenon. MHC induction by HgCi2 was self-limited, 
returning to basal levels after five weeks, despite the persis-
tence of HgCI2 administration. Induction of renal MHC expres-
sion preceded the development of immune complex deposits in 
the glomeruli. Thus it is possible that this early induction of 
MHC, or other effects of INF-,}" playa pathogenetic role in the 
later development of immune complex disease. 
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Methods 
Animals 
Male and female CBNJ mice (H_2k haplotype) and BALBI 
cCrAlt (H-2d haplotype) were used in this study. Mice were fed 
with standard mouse chow with free access to water. Mice were 
between 8 and 16 weeks old at the beginning of each experi-
ment. At least five mice per group were used in each experi-
ment. Mice were killed by neck dislocation and organs were 
harvested, snap frozen in liquid nitrogen, and stored at -70°C. 
Tissues for histological studies were embedded in Tissue-Tek 
O.C.T. (Ames Division, Miles Lavoratories Inc, Elkhart, Indi-
ana, USA), snap frozen, and stored at -70°C. 
Reagents 
Mercuric chloride was purchased from Sigma Chemicals 
(Sigma Chemical Company, St. Louis, Missouri, USA), used at 
0.35%, 0.4%, 0.7%, and 0.8% solution in 0.9% sterile saline 
serum, and injected s.c. or i.p. As control, mice were injected 
with 0.9% sterile saline serum. 
Monoclonal antibodies 
Mouse monoclonal antibodies (mAb) against monomorphic 
determinants of H-2Kk (11-4.1, IgG2a) [15], I-Ak (11-5.2.1.9, 
IgG2b) [15], H-2Dd (lgG2a) [16], and I-Ad (lgG2a) [17] were 
grown in our laboratory from cell lines obtained from American 
Type Culture Collection (ATCC). A rat anti-mouse mAb against 
interferon-y (R4-6A2, IgG1) was produced from an ATCC cell 
line [18]. Mouse mAb were purified using the Protein A method 
and the rat anti-mouse mAb was purified by precipitation with 
ammonium chloride [19]. Monoclonal antibodies were used at a 
concentration of protein of 1 mg/ml. Radioiodination of mAb 
was performed using the lodogen method [20]. 
Immunoradiometric assay for MHC products 
The assay for quantitatioh of MHC class I and class II 
products has been previously described [21]. Briefly, tissues 
were homogenized in PBS and spun at 15000 rpm for 20 minutes 
at 4°C. Supernatants were discarded and the tissue pellets, run 
in triplicate, were resuspended at a final concentration of 5 
mg/ml in PBS, and centrifugated at 3000 r.p.m. for 20 minutes at 
4°C. The pellet was then incubated with 100 J.d of the corre-
sponding iodinated mAb (100,000 cpm/100 ILl) at 4°C for one 
hour in a shaker. After washing with PBS, samples were spun at 
3000 rpm for 20 minutes at 4°C. The supernatant was discarded 
and the amount of mAb bound to the pellet was measured with 
a LKB Wallac gamma counter. Non-specific binding was deter-
mined using tissues of mice with a different H-2K haplotype and 
substracted from all experimental samples. The specificity of 
this assay has been previously demonstrated [21, 22]. 
Tissue staining 
Cryostat sections of kidneys (5 IL) were stained for H-2Kk and 
I-Ak products with the indirect immunoperoxidase technique 
using the mAb mentioned above. Briefly, after fixation of the 
slides in acetone for 10 minutes, they were incubated with 
normal goat serum (at 1:20 dilution in PBS) for 20 minutes, 
washed two times with PBS, and incubated with the mAb (at 
1:20 dilution in PBS) in a humidified camera for one hour. After 
this incubation, slides were washed in PBS three times and 
incubated for 30 minutes with peroxidase-conjugated, affinity-
purified F(ab'h goat anti-mouse IgG (Cappel Laboratories, 
West Chester, Pennsylvania, USA). After three washes in PBS, 
slides were developed with 3,3' -diaminobenzidine tetrahydro-
chloride in 0.05 HCI Tris + 0.3% hydrogen peroxide for 10 
minutes, washed with distilled water three times, counter-
stained with hematoxylin, dehydrated and mounted in Per-
mount (Fisher Scientific, Fair Lawn, New Jersey, USA). 
Northern blotting 
Total RNA from frozen kidneys was extracted using the 
guanidinium-cesium chloride method [23]. Final concentration 
of RNA was measured by spectrophotometry at absorbance of 
260 nm. Northern blot analysis was performed using 15 to 30 ILg 
of RNA for each sample, run in a 1.5% agarose, 2.2 M 
formaldehyde gel and transferred to a nitrocellullose filter. 
Filters were hybridized with random oligo-primed 32P-labeled 
cDNA probes for HLA-A3 [24], I-Aad [25], and murine INF-y 
[26]. To confirm that the same amount of RNA was loaded in 
each track, the gel was stained with ethidium bromide and the 
filters were hybridized with chicken J3-actin cDNA probe [27]. 
The amount of message for each group was semiquantitatively 
estimated by measurement of the area under the curve (AUC) 
corresponding to the densitometry of each band. For each 
group, the AUC for each message was divided by the AUC for 
the actin message, and this value was used as AUC ratio. 
Statistics 
Results are expressed as mean and standard deviation. The 
effect of various treatments was evaluated by analysis of 
variance and comparison of means done by Student's t-test 
[28]. 
Results 
HgCl2 induces systemic expression of MHC class I and class 
II products 
In CBNJ mice, administration of HgCl2 (2 mg/kg/3 x week, 
i.p.) induced class I and class II expression in kidney, heart, 
and liver, after one week of administration (Fig. 1). The MHC 
expression rose to between 2 and 14 times the levels observed 
in sham-treated mice, depending on the organ examined. 
Immunohistological staining of kidneys of mice receiving 
HgCl2 for one week showed that class I expression was induced 
mainly in proximal tubule cells. Induction in capillary endothe-
lial cells and glomerular cells was also seen. Class II induction 
was seen in proximal tubule cells and interstitial cells. More-
over, increased number of interstitial cells were detected by 
staining with anti-class II mAb. As it has been observed in other 
models [3, 4, 21, 22], expression of MHC products in renal 
tubule cells was seen in the basolateral membrane but not in the 
apical side of the cells (Fig. 2). Thus the increased class I 
expression . reflected predominantly induction of expression in 
parenchymal cells, whereas the increased class II expression 
reflected induction as well as changes of cell population (by 
infiltrating cells). 
Strain differences in HgClrinduced renal MHC expression 
The induction of renal MHC expression by HgCl2 was also 
tested in BALB/c mice, a mouse strain already reported to be 
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Fig. 1. Expression of class I and class II 
MHC products in kidney, liver and heart after 
J week of HgCl2 administration. Each group 
represents mean ± standard deviation from 5 
different mice. Class II expression in the heart 
of sham-treated mice was 35 ± 23 cpm. (S: 
organs from mice treated with saline; H: 
organs of mice treated with HgCl2 at dose of 2 
mg/kg x 3; * P < 0.05) . 
Fig. 2. Kidney sections stained with immunoperoxidase for class I and class II MHC expression. The top pictures show class I (left) and class II 
(right) MHC expression in mice treated with sham. Class I was detected in low amounts in glomerular cells and endothelium. Class II in normal 
mice is limited to some interstitial cells. The bottom pictures are from mice treated with HgCI2 for I week (left : class I, right : class 11). 
Magnification: x 16. 
susceptible to HgCl2-induced GN [9]. After one week, BALB/c 
mice developed necrotic ulcers at the site of s.c. injection of 
HgClz which healed by two to three weeks. In contrast, CBA/J 
mice did not develop ulcers. BALB/c had milder MHC induc-
tion than CBA mice, reaching significance at the second week 
(Table 1). The histological pattern of renal MHC induction was 
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Table 1. HgCl2-induced renal MHC expression in BALB/c mice 
Bound mAb 
Tubular Tubular 
H-2Kd staining I-Ad staining 
Sham 2894 ± 530 ± 1473 ± 410 
HgCI2 
I week 4113 ± 1534 +1++ 3237 ± 1667 + 
2 weeks 5928 ± 2367" +++ 3879 ± 1959" ++ 
HgCI2 was administered on alternate days at 2 mg/kg/i.p. After 1 or 2 
weeks, kidneys were harvested. Results are expressed as c.p.m. for 
bound radiolabelled mAb or as intensity of indirect immunoperoxidase 
staining. Five mice per group were studied. 
" Significantly different from sham (P < 0.05). 
Table 2. Effect of different doses of HgClz on renal MHC induction 
in CBAlJ mice 
Bound mAb 
Tubular Tubular 
H-2Kk staining I-Ak staining 
Sham 411 ± 205 ± 488 ± 182 
HgCl2 mglkg 
1.6 985 ± 686 + 790 ± 401 ± 
2 5882 ± 3762" ++++ 3597 ± 1813" ++1+++ 
3.2 5721 ± 3762" ++++ 6346 ± 3984" ++1+++ 
HgCI2 was administered on alternate days for 1 week, after which 
kidneys were harvested. Results are expressed as c.p.m. for bound 
radiolabelled mAb or as intensity of indirect immunoperoxidase stain-
ing. Five mice per group were tested . 
• Significantly different from sham (P < 0.05) 
similar for both strains; thus, further experiments were done 
using CBAlJ mice. 
Dose effect on renal MHC expression 
The effect of different regimens of HgCl2 administration on 
MHC induction was seen to be dependent on the total dose of 
HgCl2 received, within a narrow range. While administration of 
HgCl2 at dose of 1.6 mg/kg two or three times a week (total 
dose: 3.2 to 4.8 mg) did not significantly increase MHC expres-
sion in the kidney, doses ranging from 2 mg/kg/ x 3 times/week 
to 3.2 mg/kg 2 or 3 times/week (total dose: 6 to 9.6 mg) did 
increase significantly class I and class II expression (Table 2). 
However, at doses higher than 6.4 mg/week, mice developed 
signs of acute tubular necrosis. In this situation, increased class 
I and II expression was also observed but not in a dose 
dependent fashion. 
HgCl2 induces an increase in class I and II steady state 
mRNA in the kidney 
Northern blot analysis of total RNA extracted from kidneys 
of mice treated with HgCl2 showed an increase in the steady 
state mRNA levels for class I and class II mRNA (Fig. 3). The 
increase at the mRNA level was closely related to the increase 
detected at the product level by the immunoradiometric assay: 
for class I, the r value was 0.999, and for class II, 0.937 (P < 
0.05). 
Messenger RNA for INF-'}' could not be detected in total 
RNA extracted from kidneys. 
Table 3. HgClrinduced renal MHC expression: Effect of anti-IFN-y 
mAb 
Class I staining 
Tubular Interstitial 
Sham ± 
HgCl2 +++1++++ ++ 
HgClzlmAb ± ± 
Class II staining 
Tubular Interstitial 
± 
++1+++ +++1++++ 
± ± 
Results are expressed as intensity of immunoperoxidase staining 
(from - to + + + +) using anti-class I and anti-class II mAbs. The 
groups in this table represent the results from mice receiving sham, 
HgCI2 (2 mg/kg/i.p. x 3), and HgCI2 and anti-IFN-y mAb (0.1 mg/dayl 
Lp.). 
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Fig. 3. Northern blot from total RNA extractedfrom pooled kidneys of 
mice treated with sham (lane a) or HgCl2 (lane b: 1.6 mglkg x 3; lane 
c: 2 mglkg x 3; lane d: 3.2 mglkg x 3). The graph at the bottom shows 
the area under the curve (AVC) of each band expressed as a percentage 
of the AVC for /3-actin for each group (defined as AVC ratio) . 
Time course of HgCl2-induced renal MHC expression 
In experiments with long-term administration of HgCI2 , class 
I and II induction was seen to be maximal during the first week 
with marked and progressive decrease from weeks 2 to 5. After 
23 weeks of HgCl2 administration, MHC expression was not 
significantly different from that of mice receiving sterile saline 
for the same period of time (Fig. 4). Overall, the kinetics of 
MHC class II induction was similar to that of class I. Never-
theless, when the kidneys were examined histologically, local-
ization of MHC expression changed with time. Class I and class 
II expression during the first week was as described above. 
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Fig_ 4_ Time course of renal expression of 
class I and class II MHC products induced by 
HgCI2 • Each group represents mean ± 
standard deviation from 5 different mice. The 
groups with • are those significantly different 
(P < 0.05) from the sham group. (S: kidneys 
from mice treated with saline; I week, 2 
weeks, 3 weeks,S weeks, 23 weeks: kidneys 
of mice treated with HgCI2 at dose of 2 mg/kgl 
alternate days for these periods of time). 
Fig. 5. Glomerular immune complex deposits in mice treated with sham (top left) and mice treated with HgCI2 for 3 weeks (top right), 5 weeks (bottom left), and 23 weeks (bottom right). Kidney sections were stained for murine Ig with the indirect immunoperoxidase technique . 
Amplification: x 40. 
However, after two weeks and up to five weeks, the increase in 
class II expression was predominantly due to expression by 
interstitial cells, while tubular expression of both class I and 
class II decreased. Some class II-expressing interstitial cells 
were T cells as shown by the positivity of double staining with 
anti-Thy-! and anti-class II mAbs (J. Madrenas et ai, manu-
script in preparation), and were distributed in pericapillary and 
peritubular areas. At 23 weeks, no difference in MHC expres-
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Fig. 6. Class I and class II mRNA from kidneys of mice treated with 
sham (lane a) or HgCl2 (2 mglkglalternate days) for 1 week (lane b), 3 
weeks (lane c), 5 weeks (lane d), and 23 weeks (lane e). The picture at 
the bottom shows ribosomal RNA, stained with ethidium bromide, for 
each group. 
sion between mice receiving HgCl2 and those receiving sham 
could be detected. In relation to glomerular immune complex 
deposits (Fig. 5), diffuse mesangial and pericapillary deposits of 
Ig could be detected from the third week on, reaching a peak at 
five weeks. After 23 weeks of receiving HgCI2 , only small 
deposits of Ig were detected in the mesangium and pericapillar 
areas. The pattern and time course of glomerular immune 
complex deposits were similar for CBA/J and BALB/c mice. 
The results obtained at the mRNA level were similar to those 
obtained for product expression (Fig. 6). Steady state mRNA 
for MHC class I and class II decreased with time. 
Renal function was measured as BUNlbody weight ratio to 
take into account the loss of weight in mice receiving HgCI2 • It 
slightly but significantly deteriorated from the first to the fifth 
week (sham: 0.66 ± 0.06, HgCl2-treated groups: at 1 week: 1.10 
± 0.04, at 2 weeks: 1.04 ± 0.20, at 3 weeks: 0.76 ± 0.05, at 5 
weeks: 0.74 ± 0.09; analysis of variance, P < 0.05). Mice 
receiving HgCI2 for 23 weeks did not have any significant 
deterioration of renal function (BUNlbody weight = 0.70 ± 
0.07). 
Effect of anti-INF-y mAb on HgCl2-induced renal MHC 
expression 
To investigate the involvement of INF-y in the mechanism of 
MHC induction in this model of ON, experiments using anti-
INF-y mAb were performed. Administration of anti-INF-y 
mAb (0.1 mg i.p.lday from one day before starting administra-
tion of HgCI2) significantly blocked MHC induction for class I 
and class II (Fig. 7). The amount of interstitial staining for class 
I and class II, partially reflecting infiltrating cells, was minimal 
for anti-INF-y-treated mice (Table 3). Thus the anti-INF-y mAb 
blocked not only tubule cell induction but also blocked the 
increase in class II positive interstitial cells. 
Discussion 
The present experiments demonstrate that HgCl2 induces 
expression of class I and class II MHC products on renal 
parenchymal cells within a narrow dose range, and an increase 
in the interstitial cell popUlation. Both the MHC induction and 
the interstitial infiltration occur early in the response to HgCl2 
and are INF-y dependent, as shown by the blocking effect of an 
anti-INF-y mAb. The changes in the total expression of class I 
MHC products in renal homogenates seem to be due, at least in 
part, to changes in gene expression in renal parenchymal cells, 
as shown by tissue staining. Some expression, particularly for 
class II, is secondary to changes in the cell populations of the 
kidneys of mice receiving HgCI2 , either infiltrating class 11-
positive cells, or proliferation of resident cells. 
The INF-y-mediated induction of MHC expression could 
reflect either a local response to direct injury or a T cell 
response. We have recently reported that one non-specific renal 
injury, namely severe ischemic acute tubular necrosis (A TN) in 
mice, induces renal MHC expression [29]. However, several 
factors argue that ATN per se, or severe direct tubular injury, 
is not the mechanism involved in HgCl2-induced renal MHC 
expression. First, in HgCl2-induced autoimmunity, tubular in-
jury, if it occurs, is mild. Second, in ATN, we failed to show 
systemic MHC induction, which is present in the HgCI2 model 
both in mice and rats [13]. Third, the quantitative changes in 
MHC expression induced by HgCl2 were greater than those 
observed in the ATN model. Rather that a non-specific re-
sponse to injury, we believe that the induction of MHC expres-
sion by HgCI2 may be the result of a specific HgClz-induced T 
helper cell activation which leads to cytokine production. The 
fact that autoreactive T cells are found in HgCl2-induced 
autoimmunity supports this idea [11]. 
The main in vivo regulatory cytokine of MHC expression is 
INF-y [30] and its role in HgCl2-induced MHC expression 
seems to be crucial. Most of the evidence supports the idea that 
INF-y increases MHC expression through an increase of tran-
scription of MHC genes [31], although a post-transcriptional 
effect of INF-y on MHC mRNAs, by increasing the half life of 
MHC mRNAs or by alternative splicing [31, 32], cannot be 
ruled out. In our experiments, the close correlation between the 
increase in steady state mRNA levels and the increase in the 
expression of MHC products is consistent with either a tran-
scriptional or a post-transcriptional effect of INF-y. 
Our results differ from those reported by Aten et al [13] who 
were unable to detect increased class I and class II MHC 
expression in the kidneys of rats receiving HgCI2. This differ-
ence may be due in part to the quantitative approach we used in 
this study, but species differences between the rat and the 
mouse may also contribute. Rat kidney has high basal levels of 
class I expression in endothelial, glomerular epithelial and 
tubule cells, with up to 30% of such cells expressing class I [14]. 
Basal class II expression is also found in 5 to 10% of these cells 
[14, 33, 34]. Although in vitro treatment with INF-y is able to 
increase MHC expression in renal cell populations from rat 
kidneys [14]. the in vivo regulation of MHC expression may be 
more complicated. Different patterns of constitutive MHC 
expression have been reported for rat kidney [2, 33, 34]. 
Moreover, changes in MHC expression during disease are not 
consistent with findings in other species. For example, while 
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renal MHC induction can be seen in kidneys of mice undergoing 
graft-versus-host disease (OVHD) [35], no significant changes 
are detected in the kidneys of rats with OVHD [36]. These facts 
lead us to postulate that the in vivo regulation of MHC 
expression in rat kidney may be somewhat differeni from that in 
mouse kidney. The 'refractory' state of rat kidney to INF-y 
suggested by the lack of renal MHC induction by HgCl2 or 
OVHD may be attributable to many factors, such as a compet-
itive inhibition by other cytokines, as has been shown in vitro 
between INF-yand IL-4 [37]. If the rat develops HgCl2-induced 
autoimmunity without an early phase of MHC induction, this 
would suggest that the early MHC expression we observe in the 
mouse is irrelevant. However, more detailed analysis of such 
disparities wiil be necessary before reaching this co~clusion. 
It is possible that the increased renal expression of MHC or 
other INF-y-inducible molecules observed early in the response 
to HgCl2 may playa role in the later development of autoim-
mune ON [4, 38], either by triggering the autoantibody response 
or as an amplifying event in a T cell response. Class II MHC 
expression in tubular epithelium, induced by INF-yfrom T cells 
responding to HgCl2 elsewhere, could be the triggering event 
for the autoimmune response which leads to renal injury [39]. 
However, two lines of evidence suggest that increased MHC 
expression per se is not sufficient for the development of 
autoimmune injury. First, MHC induction in kidney and other 
sites by INF-y is a frequent occurrence in laboratory mice, and 
seldom leads to autoimmunity [13, 21]. The observation that 
transgenic mice consitutively expressing class II in pancreas 
islets do not develop immune-mediated diabetes is in keeping 
with this conclusion [40]. Second, although epithelial cells 
expressing class II have Ag presentation capacity, they are less 
efficient than macrophages and B cells as Ag presenting cells 
[41]. Thus, as an isolated event, the induction of high levels of 
MHC expression in renal epithelia in HgCl2-induced ON is 
unlikely to lead to autoantibody formation. However, the 
combination of HgCl2-induced renal cell injury generating al-
tered self determinants, plus high MHC expression could to-
gether favor such an outcome. It has been postulated that even 
H H+ m 
Fig. 7. Effect of anti-IFN-y mAb on HgCI2-
induced renal class I and class II MHC 
expression. Each group represents mean ± 
standard deviation from 5 different mice. 
Groups with a * are those significantly 
different (P < 0.05) from sham. (S: kidneys 
from mice treated with saline; H: kidneys 
from mice treated with HgCl2 (2 mg/kg/ x 3); 
H + m: kidneys from mice treated with HgC!2 
and anti-IFN-y mAb). 
low doses of HgCl2 damage tubule epithelium, exposing 'pro-
tected Ag' to T cells [7]. The finding of autoantibodies against a 
renal tubular antigen in the serum of mice treated with HgCl2 
supports this possibility [42]. T cell activation reSUlting from 
presentation of such auto-Ag would lead to INF-y release which 
induces MHC expression by epithelial cells. As it has been 
shown in vitro that the density of MHC expression correlates 
with the magnitude of T cell activation [43, 44], it is then 
conceivable that high MHC expression by tubule epithelial cells 
amplifies the previously triggered T cell response in this model, 
leading to massive polyclonal B cell activation and autoanti-
body formation [10]. 
The present results raise several points about the pathogen-
esis of immune renal injury induced by environmental agents . 
First, some key events, such as a change in renal gene expres-
sion, may occur early in the ,course of ON, before any immune 
complex deposits can be detected, and not at the time of 
immune complex deposition. The sequence of events in this 
model seems to be: INF-y-induced increase in MHC expres-
sion, followed by mononuclear cell infiltration, and, later, 
immune complex formation. Thus studies of renal gene expres-
sion at the time of full-blown disease may miss potentially 
important changes at earlier phases of the disease. It is likely 
that the early changes in gene expression in the kidney will play 
a role in the eventual development of autoimmune injury and 
that the progressive dissection of these early events will provide 
clues for interruption of this sequence. Second, the early phase 
of INF-y production could facilitate the activities of T and B 
cells in the autoantibody response. Recent evidence indicates 
that a T cell-dependent polycionaJ B cell activation is a common 
pathway for various forms of experimental autoimmune ON, 
including some lupus nephritis models and drug-induced ON 
[10, 45]. The B cell clones activated during some forms of 
drug-induced ON seem to be the same, as suggested by cross-
reactive idiotypes [46]. In these cases, some actions of INF-y, 
such as direct effects of B cell differentiation [47, 48], may play 
a role in the amplification of the immune response by autore-
active T helper cells, leading to B cell activation and production 
280 Madrenas et al: Renal MHC expression in HgCl2-induced GN 
of autoantibodies. Finally, the predominantly tubular MHC 
Induction as well as the pericapillary and peri tubular location of 
infiltrates in this model of GN add to the growing body of 
observations of abnormalities in the interstitial component seen 
in many cases of primary glomerular disease [49]. Such non-
glomerular events may eventually shed light on the pathogene-
sis of the glomerular processes. 
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